Analysis structure

Explore and visualize M&A dynamics in the pharmaceutical and biotechnology industries:

 executive summary

 deal trend analysis

 major deal discussion

 looking ahead

 potential targets

Key questions answered

 Explore and assess recent deals based on deal size and company type

 How is the industry using M&A as a vehicle to propel a strategy for growth?

 Delve deeper into the largest deals of 2015

 What’s the outlook for M&A in 2016?

 What companies are still out on the prowl for M&A deals?

 What companies constitute the most likely targets?

Highlights

 $437bn worth of deals has been completed in 2015 for pharmaceutical and biotechnology companies.

 Biggest deal: Pfizer’s $160bn deal terminated deal Allergan would have been biggest deal in the industry’s history

 Biggest spenders: Companies in Datamonitor Healthcare’s PharmaVitae portfolio were involved in $385bn worth of deals

 Portfolio transformation: Companies continue to explore asset stripping

 Targeted deal-making: Companies continue to gain a larger foothold in therapeutic areas of strength

 Tax-inversions: Tax-inversions have spilt over in 2015

 2016 Outlook: Pipeline-centric acquisitions will continue to bolster companies that have remained largely passive

About the PharmaVitae Team

 Datamonitor Healthcare’s PharmaVitae team tracks and forecasts the performance of the top 35 pharmaceutical and biotechnology

companies operating in the global prescription pharmaceutical market.

 For more information about the PharmaVitae Team, please contact Ali Al-Bazergan, Lead Analyst: ali.al-bazergan@informa.com

About the data

 Deal information was sourced from MedTrack, in which dates refer to completion rather than announced

 Deals by segments refer to the type of company being acquired irrespective to the industry of the acquirer.